the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before August 11, 2020. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before August 3, 2020. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by August 4, 2020.

Closed Committee Deliberations: On August 18, 2020, from 11:30 a.m. to 12 p.m. (CST), the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussion of information concerning individuals associated with the research programs at the NCTR.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Donna Mendrick at least 14 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111482.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).


Lowell J. Schiller,
Principal Associate Commissioner for Policy.

[FR Doc. 2020–15524 Filed 7–16–20; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Charter Renewal for the Advisory Commission on Childhood Vaccines

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: In accordance with the Federal Advisory Committee Act, HHS is hereby giving notice that the Advisory Commission on Childhood Vaccines (ACCV) charter has been renewed. The effective date of the renewed charter is July 20, 2020.

FOR FURTHER INFORMATION CONTACT: Tamara Overby, Designated Federal Officer, Healthcare Systems Bureau, HRSA, 5600 Fishers Lane, 08N186A, Rockville, Maryland 20857; 301–443–3766; or toverby@hrsa.gov.

SUPPLEMENTARY INFORMATION: The ACCV was established by section 2119 of the Public Health Service Act (the Act) (42 U.S.C. 300aa–19), as enacted by Public Law (Pub. L.) 99–660, and as subsequently amended, and advises the Secretary of Health and Human Services (the Secretary) on issues related to the implementation of the National Vaccine Injury Compensation Program (VICP). Other activities of the ACCV include: Recommending changes in the Vaccine Injury Table at its own initiative or as the result of the filing of a petition; advising the Secretary in implementing section 2127 of the Act regarding the need for childhood vaccination products that result in fewer or no significant adverse reactions; surveying federal, state, and local programs and activities related to gathering information on injuries associated with the administration of childhood vaccines, including the adverse reaction reporting requirements of section 2123(b) of the Act; advising the Secretary on the methods of obtaining, compiling, publishing, and using credible data related to the frequency and severity of adverse reactions associated with childhood vaccines; consulting on the development or revision of Vaccine Information Statements; and recommending to the Director of the National Vaccine Program research related to vaccine injuries which should be conducted to carry out the VICP.

The renewed charter for the ACCV was approved on July 20, 2020, which will also stand as the filing date. Renewal of the ACCV charter gives authorization for the commission to operate until July 20, 2022.

A copy of the ACCV charter is available on the ACCV's website at https://www.hrsa.gov/advisory-committees/vaccines/index.html. A copy of the charter also can be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The website address for the FACA database is http://www.facadatabase.gov/.

Maria G. Button,
Director, Executive Secretariat.

[FR Doc. 2020–15494 Filed 7–16–20; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Presidential Advisory Council on HIV/AIDS

AGENCY: Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

ACTION: Notice of a virtual meeting.

SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that the Presidential Advisory Council on HIV/AIDS (PACHA or the Council) will be holding the 68th full Council meeting utilizing virtual technology. PACHA members will be discussing novel coronavirus (COVID–19) and HIV, and Ready, Set, PrEP enrollment. The meeting will be open to the public; a public comment session will be held during the meeting. Pre-registration is required to provide public comment.

DATES: The meeting will be held on Thursday, August 6, from approximately 3:00 p.m. to 5:00 p.m. (ET). This meeting will be conducted utilizing virtual technology.

ADDRESSES: Instructions regarding attending this meeting virtually will be posted one week prior to the meeting at: https://www.hiv.gov/federal-response/pacha/about-pacha.

FOR FURTHER INFORMATION CONTACT: Ms. Caroline Talev, MPA, Public Health Analyst, Presidential Advisory Council on HIV/AIDS, 330 C Street SW, Room L609A, Washington, DC 20024; (202) 795–7622 or PACHA@hhs.gov. Additional information can be obtained by accessing the Council’s page on the HIV.gov site at www.hiv.gov/pacha.

SUPPLEMENTARY INFORMATION: Individuals who wish to participate in the meeting and/or provide public
comment should pre-register by sending an email to PACHA@hhs.gov by close of business Thursday, July 30, 2020. Individuals will be required to provide their name, organization, and email address to pre-register. If you decide you would like to provide public comment and do not pre-register by the deadline, you have an opportunity to submit your written statement by emailing PACHA@hhs.gov by close of business Thursday, August 13, 2020. The meeting agenda will be posted on the PACHA website at https://www.hiv.gov/federal-response/pacha/about-pacha as soon as it becomes available.

PACHA was established by Executive Order 12963, dated June 14, 1995, as amended by Executive Order 13009, dated June 14, 1996 and is currently operating under the authority given in Executive Order 13389, dated September 27, 2019. The Council was established to provide advice, information, and recommendations to the Secretary regarding programs and policies intended to promote effective prevention and care of HIV infection and AIDS. The functions of the Council are solely advisory in nature.

The Council consists of not more than 25 members. Council members are selected from prominent community leaders with particular expertise in, or knowledge of, matters concerning HIV and AIDS, public health, global health, philanthropy, marketing or business, as well as other national leaders held in high esteem from other sectors of society. Council members are appointed by the Secretary or designee, in consultation with the White House.

Dated: July 1, 2020.

B. Kaye Hayes,
Principal Deputy Director, Office of Infectious Disease and HIV/AIDS Policy, Executive Director, Presidential Advisory Council on HIV/AIDS, Office of the Assistant Secretary for Health, Department of Health and Human Services.

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting:
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Pediatric Formulations and Drug Delivery Systems and Psychoactive Surveillance.
Date: August 6, 2020.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual meeting).
Contact Person: Mary Custer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892, (301) 480–1164, custerm@csr.nih.gov.


Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Board on Medical Rehabilitation Research.
The meeting will be open to the public and held as a virtual meeting. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Advisory Board on Medical Rehabilitation Research.
Date: August 18, 2020.
Time: 11:00 a.m. to 3:00 p.m. (EST).
Agenda: NICHD Director’s report; NCMRR Director’s report; Updates on the NIH Rehabilitation Research Conference and NIH Rehabilitation Research Plan; Scientific presentation on Data Science in Rehabilitation; Agenda Planning for the next Board meeting.
Place: National Center for Medical Rehabilitation Research, Eunice Kennedy Shriver National Institute, of Child Health and Human Development, NIH, DHHS, 6710B Rockledge Drive, Room 2116, Bethesda, MD 20892–7002 (Virtual Meeting).
Contact Person: Ralph M. Nitkin, Ph.D., Deputy Director, National Center for Medical Rehabilitation Research, Eunice Kennedy Shriver National Institute, of Child Health and Human Development, NIH, DHHS, 6710B Rockledge Drive, Room 2116, Bethesda, MD 20892–7002, Phone: (301) 402–4206, Email: RNN21e@nih.gov.

The meeting will be NIH VideoCast. Please select the following link for VideoCast on the day of the meeting: https://videocast.nih.gov/default.asp.
Information is also available on the Institute’s/Center’s home page: http://www.nichd.nih.gov/about/advisory/nabmr/Pages/index.aspx where the current roster and minutes from past meetings are posted. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Institute of Neurological Disorders and Stroke Special Emphasis Panel, July 10, 2020, 10:00 a.m. to July 10, 2020, 03:30 p.m., National Institutes of Health Rockville, MD 20852 which was published in the Federal Register on July 01, 2020, 85FR574.

This meeting notice is to change the ZNS1 SRB–G 30 July 10, 2020 SEP meeting date to July 27, 2020. The meeting is closed to the public.

Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.